OBJECTIVE: To investigate the contribution of biomarkers of glucose homeostasis (adiponectin, glucose, glycated albumin, and insulin levels) and inflammation (high-sensitivity C-reactive protein and lipoprotein-associated phospholipase A(2) levels) to the risk of developing Alzheimer disease (AD) and all-cause dementia. DESIGN: Prospective cohort study. SETTING: Dementia-free Framingham Heart Study participants had sera measured for these biomarkers at the 19th biennial examination (1985-1988) and were followed up prospectively for the development of AD and all-cause dementia. PARTICIPANTS: Eight hundred forty (541 women, median age of 76 years) subjects participated in the study. MAIN OUTCOME MEASURES: We used sex-pooled and sex-specific multivariable Cox proportional hazards models adjusted for age, education, body mass index, recent change in weight, APOE ε4 allele status, and plasma docosahexaenoic acid levels to determine association of these biomarkers with the development of all-cause dementia and AD. RESULTS: Over a mean follow-up period of 13 years, 159 persons developed dementia (including 125 with AD). After adjustment for other risk factors, only adiponectin in women was associated with an increased risk of all-cause dementia (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.00-1.66; P=.054) and AD (HR, 1.33; 95% CI, 1.00-1.76; P=.050) per 1-SD increase in adiponectin level. Women with baseline adiponectin values more than the median had a higher risk of all-cause dementia (HR, 1.63; 95% CI, 1.03-2.56; P=.04) and AD (HR, 1.87; 95% CI, 1.13-3.10; P=.01) as compared with those with values less than the median. CONCLUSION: In women, increased plasma adiponectin levels are an independent risk factor for the development of both all-cause dementia and AD.
OBJECTIVE: To investigate the contribution of biomarkers of glucose homeostasis (adiponectin, glucose, glycated albumin, and insulin levels) and inflammation (high-sensitivity C-reactive protein and lipoprotein-associated phospholipase A(2) levels) to the risk of developing Alzheimer disease (AD) and all-cause dementia. DESIGN: Prospective cohort study. SETTING:Dementia-free Framingham Heart Study participants had sera measured for these biomarkers at the 19th biennial examination (1985-1988) and were followed up prospectively for the development of AD and all-cause dementia. PARTICIPANTS: Eight hundred forty (541 women, median age of 76 years) subjects participated in the study. MAIN OUTCOME MEASURES: We used sex-pooled and sex-specific multivariable Cox proportional hazards models adjusted for age, education, body mass index, recent change in weight, APOE ε4 allele status, and plasma docosahexaenoic acid levels to determine association of these biomarkers with the development of all-cause dementia and AD. RESULTS: Over a mean follow-up period of 13 years, 159 persons developed dementia (including 125 with AD). After adjustment for other risk factors, only adiponectin in women was associated with an increased risk of all-cause dementia (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.00-1.66; P=.054) and AD (HR, 1.33; 95% CI, 1.00-1.76; P=.050) per 1-SD increase in adiponectin level. Women with baseline adiponectin values more than the median had a higher risk of all-cause dementia (HR, 1.63; 95% CI, 1.03-2.56; P=.04) and AD (HR, 1.87; 95% CI, 1.13-3.10; P=.01) as compared with those with values less than the median. CONCLUSION: In women, increased plasma adiponectin levels are an independent risk factor for the development of both all-cause dementia and AD.
Authors: K Yaffe; K Lindquist; B W Penninx; E M Simonsick; M Pahor; S Kritchevsky; L Launer; L Kuller; S Rubin; T Harris Journal: Neurology Date: 2003-07-08 Impact factor: 9.910
Authors: W J Strittmatter; K H Weisgraber; D Y Huang; L M Dong; G S Salvesen; M Pericak-Vance; D Schmechel; A M Saunders; D Goldgaber; A D Roses Journal: Proc Natl Acad Sci U S A Date: 1993-09-01 Impact factor: 11.205
Authors: R H Myers; E J Schaefer; P W Wilson; R D'Agostino; J M Ordovas; A Espino; R Au; R F White; J E Knoefel; J L Cobb; K A McNulty; A Beiser; P A Wolf Journal: Neurology Date: 1996-03 Impact factor: 9.910
Authors: Linda Broer; Julia Raschenberger; Joris Deelen; Massimo Mangino; Veryan Codd; Kirsi H Pietiläinen; Eva Albrecht; Najaf Amin; Marian Beekman; Anton J M de Craen; Christian Gieger; Margot Haun; Peter Henneman; Christian Herder; Iiris Hovatta; Annika Laser; Lyudmyla Kedenko; Wolfgang Koenig; Barbara Kollerits; Eeva Moilanen; Ben A Oostra; Bernhard Paulweber; Lydia Quaye; Aila Rissanen; Michael Roden; Ida Surakka; Ana M Valdes; Katriina Vuolteenaho; Barbara Thorand; Ko Willems van Dijk; Jaakko Kaprio; Tim D Spector; P Eline Slagboom; Nilesh J Samani; Florian Kronenberg; Cornelia M van Duijn; Karl-Heinz Ladwig Journal: Eur J Epidemiol Date: 2014-07-27 Impact factor: 8.082
Authors: Adina Zeki Al Hazzouri; Mary N Haan; Rachel A Whitmer; Kristine Yaffe; John Neuhaus Journal: Dement Geriatr Cogn Disord Date: 2012-07-17 Impact factor: 2.959
Authors: Margarete A Wichmann; Karen J Cruickshanks; Cynthia M Carlsson; Rick Chappell; Mary E Fischer; Barbara E K Klein; Ronald Klein; Michael Y Tsai; Carla R Schubert Journal: J Am Geriatr Soc Date: 2014-08-14 Impact factor: 5.562
Authors: Annette L Fitzpatrick; Michael C Irizarry; Mary Cushman; Nancy S Jenny; Gloria C Chi; Carol Koro Journal: Atherosclerosis Date: 2014-05-22 Impact factor: 5.162
Authors: J M Arbones-Mainar; L A Johnson; E Torres-Perez; A E Garcia; S Perez-Diaz; J Raber; N Maeda Journal: Int J Obes (Lond) Date: 2016-05-10 Impact factor: 5.095